269 related articles for article (PubMed ID: 12427421)
1. Cardiac manifestations of Anderson-Fabry disease in heterozygous females.
Kampmann C; Baehner F; Whybra C; Martin C; Wiethoff CM; Ries M; Gal A; Beck M
J Am Coll Cardiol; 2002 Nov; 40(9):1668-74. PubMed ID: 12427421
[TBL] [Abstract][Full Text] [Related]
2. New insights in cardiac structural changes in patients with Fabry's disease.
Linhart A; Palecek T; Bultas J; Ferguson JJ; Hrudová J; Karetová D; Zeman J; Ledvinová J; Poupetová H; Elleder M; Aschermann M
Am Heart J; 2000 Jun; 139(6):1101-8. PubMed ID: 10827394
[TBL] [Abstract][Full Text] [Related]
3. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular radial strain impairment precedes hypertrophy in Anderson-Fabry disease.
Spinelli L; Giugliano G; Imbriaco M; Esposito G; Nappi C; Riccio E; Ponsiglione A; Pisani A; Cuocolo A; Trimarco B
Int J Cardiovasc Imaging; 2020 Aug; 36(8):1465-1476. PubMed ID: 32306159
[TBL] [Abstract][Full Text] [Related]
5. Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease.
Tomberli B; Cecchi F; Sciagrà R; Berti V; Lisi F; Torricelli F; Morrone A; Castelli G; Yacoub MH; Olivotto I
Eur J Heart Fail; 2013 Dec; 15(12):1363-73. PubMed ID: 23818648
[TBL] [Abstract][Full Text] [Related]
6. Right Ventricular Hypertrophy, Systolic Function, and Disease Severity in Anderson-Fabry Disease: An Echocardiographic Study.
Graziani F; Laurito M; Pieroni M; Pennestrì F; Lanza GA; Coluccia V; Camporeale A; Pedicino D; Verrecchia E; Manna R; Crea F
J Am Soc Echocardiogr; 2017 Mar; 30(3):282-291. PubMed ID: 28069318
[TBL] [Abstract][Full Text] [Related]
7. Clinical study of left ventricular structure and function in patients with Anderson-Fabry disease before and after enzyme replacement therapy.
Huang S; Wang J; Zhang W; Gao F; Chen Y; Shui W; Xing X; Chen S; Mu Y
J Clin Ultrasound; 2024 Jan; 52(1):20-29. PubMed ID: 37883130
[TBL] [Abstract][Full Text] [Related]
8. The heart in Anderson Fabry disease.
Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
[TBL] [Abstract][Full Text] [Related]
9. Cardiac manifestations in Fabry disease.
Linhart A; Lubanda JC; Palecek T; Bultas J; Karetová D; Ledvinová J; Elleder M; Aschermann M
J Inherit Metab Dis; 2001; 24 Suppl 2():75-83; discussion 65. PubMed ID: 11758683
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
11. Systolic myocardial mechanics in patients with Anderson-Fabry disease with and without left ventricular hypertrophy and in comparison to nonobstructive hypertrophic cardiomyopathy.
Gruner C; Verocai F; Carasso S; Vannan MA; Jamorski M; Clarke JT; Care M; Iwanochko RM; Rakowski H
Echocardiography; 2012 Aug; 29(7):810-7. PubMed ID: 22497597
[TBL] [Abstract][Full Text] [Related]
12. Early detection of Fabry cardiomyopathy by tissue Doppler imaging.
Pieroni M; Chimenti C; Ricci R; Sale P; Russo MA; Frustaci A
Circulation; 2003 Apr; 107(15):1978-84. PubMed ID: 12668521
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: a functional and anatomical study of cardiac manifestations in 20 hemizygous male patients.
Senechal M; Germain DP
Clin Genet; 2003 Jan; 63(1):46-52. PubMed ID: 12519371
[TBL] [Abstract][Full Text] [Related]
14. Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease.
Putko BN; Yogasundaram H; Chow K; Pagano J; Khan A; Paterson DI; Thompson RB; Oudit GY
Eur Heart J Cardiovasc Imaging; 2015 Oct; 16(10):1129-36. PubMed ID: 25750198
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity.
Wu JC; Ho CY; Skali H; Abichandani R; Wilcox WR; Banikazemi M; Packman S; Sims K; Solomon SD
Eur Heart J; 2010 May; 31(9):1088-97. PubMed ID: 20061327
[TBL] [Abstract][Full Text] [Related]
16. Onset and progression of the Anderson-Fabry disease related cardiomyopathy.
Kampmann C; Linhart A; Baehner F; Palecek T; Wiethoff CM; Miebach E; Whybra C; Gal A; Bultas J; Beck M
Int J Cardiol; 2008 Nov; 130(3):367-73. PubMed ID: 18572264
[TBL] [Abstract][Full Text] [Related]
17. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
Niemann M; Herrmann S; Hu K; Breunig F; Strotmann J; Beer M; Machann W; Voelker W; Ertl G; Wanner C; Weidemann F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):592-601. PubMed ID: 21679893
[TBL] [Abstract][Full Text] [Related]
18. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
Putko BN; Wen K; Thompson RB; Mullen J; Shanks M; Yogasundaram H; Sergi C; Oudit GY
Heart Fail Rev; 2015 Mar; 20(2):179-91. PubMed ID: 25030479
[TBL] [Abstract][Full Text] [Related]
19. Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis.
Kampmann C; Linhart A; Devereux RB; Schiffmann R
Clin Ther; 2009 Sep; 31(9):1966-76. PubMed ID: 19843486
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease.
Deva DP; Hanneman K; Li Q; Ng MY; Wasim S; Morel C; Iwanochko RM; Thavendiranathan P; Crean AM
J Cardiovasc Magn Reson; 2016 Mar; 18():14. PubMed ID: 27036375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
